Compare iShares China Large-Cap ETF (FXI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Revvity Inc — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 4.4× iShares China Large-Cap ETF's market cap, and Revvity Inc pays a 0.18% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Revvity Inc for 12 Days on average.
| FXI | RVTY | |
|---|---|---|
Market Cap | $3.86B | $16.98B |
Volume | 16,323,837 | 1,456,900 |
52-Week High | $41.08 | $157.36 |
52-Week Low | $31.59 | $82.26 |
Typical Hold Time | 150 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
